Cocrystal Pharma, Inc.
COCP
$1.31
$0.010.77%
NASDAQ
| 12/31/2025 | 09/30/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | 69.71% | -14.97% | |||
| Gross Profit | -69.71% | 14.97% | |||
| SG&A Expenses | -24.05% | 15.11% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 18.76% | -0.90% | |||
| Operating Income | -18.76% | 0.90% | |||
| Income Before Tax | -18.40% | 0.29% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -18.40% | 0.29% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -18.40% | 0.29% | |||
| EBIT | -18.76% | 0.90% | |||
| EBITDA | -18.88% | 0.53% | |||
| EPS Basic | 5.79% | 7.72% | |||
| Normalized Basic EPS | 5.75% | 7.69% | |||
| EPS Diluted | 5.79% | 7.72% | |||
| Normalized Diluted EPS | 5.75% | 7.69% | |||
| Average Basic Shares Outstanding | 25.68% | 8.03% | |||
| Average Diluted Shares Outstanding | 25.68% | 8.03% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||